New research!

The SARS-CoV-2 B.

The feature of B.

ACE2 receptor dominates virus fusion and entry, becoming the target of neutralizing antibodies.

On May 27, researchers from the Pasteur Institute in France published a study on the preprint biorxiv, which showed that the Pfizer vaccine seems to prevent the Indian virus strain, but the effect is mediocre .

The Pfizer vaccine seems to prevent the Indian virus strain, but the effect is mediocre.

Delphine Planas et al, Reduced sensitivity of infectious SARS-CoV-2 variant B.

Delphine Planas et al, Reduced sensitivity of infectious SARS-CoV-2 variant B.

When the sera of convalescent patients and Pfizer vaccinators were collected within 12 months after the onset of symptoms, it was found that the effectiveness of B.

The effective power of B.

The results of this paper found that the variant modified the ACE2 binding area at the periphery of the cell to avoid antibody recognition and effectively bind to ACE2.

The variant modified the ACE2 binding area on the periphery of the cell to avoid antibody recognition and effectively bind to ACE2.

B.

In the second batch of recovered patients (M12), the half effective dose (ED50) of B.

Vaccination of previously infected people is likely to have a preventive effect on a large number of circulating virus strains (including B.

When sampling at 8 and 16 weeks after vaccination, two doses of Pfizer vaccine produced higher serum neutralization levels for B.

Sensitivity of SARS-CoV-2 D614G, B.

Sensitivity of SARS-CoV-2 D614G, B.
1.
1.
7, B.
1.
351 and B.
1.
617.
2 variants to the serum of convalescent patients and vaccinators

A recent report analyzed asymptomatic cases in England and estimated the impact of the vaccine on B.
1.
617.
2 infection.
Compared with B.
1.
1.
7, after 1 dose of AstraZeneca vaccine, B.
1.
617.
2 The effectiveness (33.
5%) is significantly lower than B.
1.
1.
7 (51%).
It is estimated that the effectiveness of the AstraZeneca and Pfizer vaccines for the two doses of B.
1.
617.
2 is 60% and 88%, respectively.
Therefore, the antibodies induced by AstraZeneca vaccine are less effective against B.
1.
351 and B.
1.
617.
2 than those induced by Pfizer vaccine.

Compared with B.
1.
1.
7, after 1 dose of AstraZeneca vaccine, the effectiveness (33.
5%) of B.
1.
617.
2 was significantly lower than that of B.
1.
1.
7 (51%).
It is estimated that the effectiveness of the AstraZeneca and Pfizer vaccines for the two doses of B.
1.
617.
2 is 60% and 88%, respectively.
Therefore, the antibodies induced by AstraZeneca vaccine are less effective against B.
1.
351 and B.
1.
617.
2 than those induced by Pfizer vaccine.
Compared with B.
1.
1.
7, after 1 dose of AstraZeneca vaccine, the effectiveness (33.
5%) of B.
1.
617.
2 was significantly lower than that of B.
1.
1.
7 (51%).
It is estimated that the effectiveness of the AstraZeneca and Pfizer vaccines for the two doses of B.
1.
617.
2 is 60% and 88%, respectively.
Therefore, the antibodies induced by AstraZeneca vaccine are less effective against B.
1.
351 and B.
1.
617.
2 than those induced by Pfizer vaccine.

The research results also showed that: B.
617.
2 variant obviously escaped the neutralizing antibody and polyclonal antibody (cocktail therapy) in NTD and RBD region .

B.
617.
2 variant obviously escaped the neutralizing antibody and polyclonal antibody in NTD and RBD region (cocktail therapy) B.
617.
2 variant obviously escaped the neutralizing antibody and polyclonal antibody in NTD and RBD region (cocktail therapy)

Original source:

https:// target="_blank" rel="noopener">https://

Leave a message here